Megestrol acetate in the treatment of hormone refractory prostate cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 3, 1997, Pages 308-310

  Osborn, Jennifer L ^a   Smith, David C ^a   Trump, Donald L ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b Liliane Kaufmann Building ^*  (United States)

Author keywords

Megestrol acetate; Prostate

Indexed keywords

MEGESTROL ACETATE; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ARTICLE; CANCER HORMONE THERAPY; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG EFFICACY; HUMAN; MALE; PROSTATE CANCER; TREATMENT FAILURE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; DRUG MONITORING; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MEGESTROL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 0030996883     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199706000-00021     Document Type: Article

References (13)

1. Geller J, Albert J, Geller S, Lopez D, Cantor T, Yen S. Effect of megestrol acetate (megace) on steroid metabolism and steroid-protein binding in the human prostate. J Clin Endocrinol Metab 1976;43:1000-8.
2. Geller J, Albert J, Yen SS. Treatment of advanced cancer of the prostate with megestrol acetate. Urology 1978;12:537-41.
3. Block M, Bonomi P, Anderson K, Wolter J, Showel J, Pessis D, Slayton R. Treatment of stage D prostatic carcinoma with megestrol acetate. J Surg Oncol 1981;17:367-71.
4. Miller JI, Ahmann FR, Drach GW, Emerson SS, Bottaccini MR. The clinical usefulness of serum prostate specific antigen after hormonal therapy for metastatic prostate cancer. J Urol 1992;147:956-61.
5. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urologic Research Group Studies. NCI Monogr 1988;7:165-70.
6. Scott WW, Menon M, Walsh PC. Hormonal therapy of prostate cancer. Cancer 1980;45:1926-36.
7. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-24.
8. Venner PM, Klotz PG, Klotz LH, Stewart DJ, Davis IR, Orovan WL, Ramsey EW. Megestrol acetate plus minidose diethylstilbestrol in the treatment of carcinoma of the prostate. Semin Oncol 1988; 15(suppl 1):62-7.
9. Venner PM. Therapeutic options in treatment of advanced carcinoma of the prostate. Semin Oncol 1990; 17(6 suppl 9):73-7.
10. Crombie C, Raghaven D, Page J, Woods R, Dalley D, Devine R, Rosen M. Phase II study of megestrol acetate for metastatic carcinoma of the prostate. Br J Urol 1987;59:443-6.
11. Daniel F, MacLeod PM, Tyrrell CJ. Megestrol acetate in relapsed carcinoma of the prostate. Br J Urol 1990;65:275-7.
12. McLeod DG, Murphy GP, Priore R. Comparison of megace, stilphostrol, megace plus DES, or streptozotocin in metastatic prostate cancer in patients with hormone failure and prior radiotherapy. Urology 1988;32:431-6.
13. Dawson NA, Conaway M, Winer EP, Lake D, Small EJ, Cooper MR, Green MR, Ernstoff M, Vogelzang NJ. A randomized study comparing standard versus moderately high dose megestrol acetate in advanced prostate cancer: a cancer and leukemia group B study. [Abstract] Proc Am Assoc Clin Oncol 1995; 14:236.